GlassScriptPhysician profile
Jeanine Werner
NPI 1366473118
$6,740.06
in general payments reported to CMS, 2019-2025
66 companies · $2,459 in 2025
The $2,459 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,948 · 2020: $394 · 2021: $275 · 2022: $135 · 2023: $147 · 2024: $1,381 · 2025: $2,459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,671 · Education: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,671.30 |
| Education | $316.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $573.81 | 2019-2025 | Verzenio, Jaypirca |
| Novartis Pharmaceuticals Corporation | $525.23 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $493.29 | 2019-2025 | Enhertu, Lynparza, Calquence |
| E.R. Squibb & Sons, L.L.C. | $408.64 | 2019-2025 | Opdivo, Augtyro, Krazati |
| Abbvie INC. | $296.94 | 2019-2025 | |
| Glaxosmithkline, LLC. | $263.66 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Genentech USA, INC. | $242.69 | 2019-2025 | Polivy, Venclexta, Itovebi |
| Pfizer INC. | $223.59 | 2019-2025 | |
| Genzyme Corporation | $220.42 | 2019-2025 | |
| Janssen Biotech, INC. | $206.07 | 2019-2024 | Carvykti, Rybrevant |
| Merck Sharp & Dohme LLC | $202.81 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Daiichi Sankyo INC. | $190.51 | 2020-2025 | Enhertu, Injectafer |
| Celgene Corporation | $171.48 | 2019-2025 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $162.21 | 2019-2025 | Alunbrig, Iclusig, Vpriv |
| Gilead Sciences, INC. | $148.21 | 2019-2025 | Trodelvy |
Show all 63 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeanine Werner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.